Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Cardiovascular endocrinology

Long-term safety of growth hormone

Adults born small for gestational age (SGA) are ideal candidates for growth hormone (GH) therapy to promote catch-up growth and increase adult height. However, the long-term consequences of GH treatment on cardiovascular risk and mortality remain unclear. Now, data from the first longitudinal study assessing cardiovascular risk factors in SGA adults has shown that long-term GH treatment had no unfavourable cardiovascular effects and improved lipid profiles during the 5 years after cessation of GH therapy.

The study included 199 SGA young adults who were treated with GH and three age-matched control groups (n = 285), including untreated SGA adults. Patients were evaluated for longitudinal changes in cardiovascular parameters at GH cessation, with follow-up at 6 months, 2 years and 5 years.

In SGA adults, mean systolic and diastolic blood pressure temporarily increased at 6 months after GH discontinuation (P < 0.001 for both comparisons), but returned to levels similar to baseline at 5 years (systolic, P = 0.126; diastolic, P = 0.455). At 5 years, non-significant increases in lipid concentrations were observed and carotid intima-media thickness (cIMT) remained unchanged. Compared with short SGA adults who were not treated with GH (n = 51), mean cholesterol (P = 0.0030) and LDL cholesterol (P < 0.0001) levels were markedly lower and mean blood pressure and cIMT were not significantly different (P > 0.12 for all comparisons) in the treated group at 5 years after cessation of GH therapy. In addition, mean blood pressure, cIMT and lipid concentrations of treated patients at 5 years after cessation were not different from those of untreated SGA adults with spontaneous catch-up growth (n = 92).

Overall, the findings offer important insight into the long-term cardiovascular health implications associated with GH therapy following treatment cessation in SGA adults.

References

  1. 1

    van der Steen, M., Kerkhof, G.F., Smeets C.C.J. and Hokken-Koelega, A.C.S. Cardiovascular risk factors and carotid intima media thickness in young adults born small for gestational age after cessation of growth hormone treatment: a 5-year longitudinal study. Lancet Diabetes Endocrinol. http://dx.doi.org/10.1016/S2213-8587(17)30311-X (2017)

Download references

Authors

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bradley, C. Long-term safety of growth hormone. Nat Rev Endocrinol 14, 3 (2018). https://doi.org/10.1038/nrendo.2017.155

Download citation

Search

Quick links